When was Chiasma founded?

Chiasma was founded in 2001 and raised its 1st funding round 10 years after it was founded.

Where is Chiasma located?

Chiasma is headquartered in Needham, United States.

Is Chiasma a funded company?

Chiasma is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Jun 11, 2011.

How much is Chiasma worth?

The last known valuation of Chiasma was $***** as of Apr 26, 2019.

When was the latest funding round of Chiasma?

Chiasma's latest funding was a $***** Conventional Debt round on Jun 11, 2011, with participation from 0 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $919M in funding in 2026 to date.

Where does Chiasma rank among its competitors?

Chiasma ranks 73rd amongst 107 active competitors, of which 38 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Chiasma?

Chiasma's top competitors include BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Chiasma - 2026 Company Profile, Team, Funding & Competitors

Chiasma is an acquired company based in Needham (United States), founded in 2001. It operates as a Developer of therapies for treating rare and debilitating diseases. Chiasma has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 107 active competitors, including 38 funded and 36 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics.

Company Details

Chiasma is developing therapies for treating rare and debilitating diseases. The company offers its proprietary technology platform, Transient Permeability Enhancer (TPE). Through this platform, the company is developing oral medications that are only available as injections. Their lead candidate Mycapssa (octreotide capsules) is used for treating acromegaly. The candidate is in phase III clinical trials and company products are FDA approved.

Website: chiasma.com
Email ID: *****@chiasmapharma.com
Phone Number: +1 **********

Key Metrics

Founded Year

2001

Location

Needham, United States

Stage

Acquired

Latest Funding Round

Conventional Debt, Jun 11, 2011, $*****

Last Known Valuation

$***** as on Apr 26, 2019

Ranked

73^rd among 107 active competitors

Similar Companies

BioMarin Pharmaceutical & 129 more

Exit Details

Acquired by Amryt Pharma (May 04, 2021)

View Chiasma's full profile

Chiasma got acquired by Amryt Pharma on May 04, 2021.

Click here to take a look at Chiasma's acquisition in detail

Chiasma has raised funding over 1 round.

Here is the list of recent funding rounds of Chiasma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 11, 2011	8355520	Conventional Debt	3689190	9892456	9977352	8604458

Access funding benchmarks and valuations. Sign up today!

View details of Chiasma's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Chiasma include BioMarin Pharmaceutical, Ultragenyx and CRISPR Therapeutics. Here is the list of Top 10 competitors of Chiasma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
3rd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
4th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Arch Venture Partners & 9 others	63/100
5th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
6th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Oberland Capital ... & 9 others	61/100
7th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Gilde Healthcare & 7 others	61/100
8th	Pharvaris 2015, Leiden (Netherlands), Public	Orally deliverable bradykinin B2 antagonists for hereditary angioedema	$164M	Foresite Capital, Life Sciences Partners & 9 others	61/100
9th	American Gene 2008, Rockville (United States), Series B	Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases	$53.1M	Ride wave ventures, Gaingels & 5 others	61/100
10th	Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised	Small molecule drug reformulation and repurposing for orphan indications	-	robinson-family.ca, Michael A Tory Trust ... & 31 others	59/100
73rd	Chiasma 2001, Needham (United States), Acquired	Developer of therapies for treating rare and debilitating diseases	-	-	31/100